Skip to main content
AAWH
OTC Life Sciences

Ascend Q3: Revenue $130.0M, Gross Margin 40.8%, Cash Down to $63.6M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.35
Mkt Cap
$71.186M
52W Low
$0.34
52W High
$1.2
52W Position info
3.2% above low
Off High info
71% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

AAWH is trading near its 52-week low of $0.34 (3.2% above the low).

Summary

Ascend's Q3 revenue rose 4% to $130.0 million with gross margin at 40.8%, but finance-lease interest pushed the net loss to $28.0 million and cash down to $63.6 million.


Key Events · Earnings and Guidance · AAWH

  • Q3 Revenue Up 4% to $130.0M

    Revenue rose $5,285 thousand, or 4%, to $130,019 thousand, driven by $18,126 thousand of incremental partner and new-store revenue, partly offset by an $8,755 thousand wholesale decline.

  • Gross Margin Jumps to 40.8%

    Gross profit was $53,089 thousand at a 40.8% margin versus 35.0% a year earlier, helped by $6,748 thousand of lower inventory write-downs; operating profit was $4,500 thousand against a $1,325 thousand loss.

  • Interest Expense Up 75%

    Interest expense rose $9,415 thousand to $21,977 thousand, including $8,134 thousand of higher finance-lease interest, driving a net loss of $27,951 thousand, or $0.14 per share.

  • Cash Falls to $63.6M

    Cash and equivalents dropped $22,051 thousand in nine months to $63,625 thousand after $38,849 thousand of interest paid and a $17,000 thousand litigation settlement; management says liquidity covers the next twelve months.


Analysis · AAWH · Life Sciences

The operating line finally turned positive, but interest expense is eating the improvement. Revenue grew 4% to $130.0 million and gross margin jumped to 40.8% from 35.0%, producing a $4.5 million operating profit versus a year-ago loss. Interest expense, however, rose 75% to $22.0 million as finance-lease interest alone climbed $8.1 million, leaving a $28.0 million quarterly net loss. Cash fell $22.1 million in nine months to $63.6 million after $38.8 million of interest paid and a $17.0 million litigation settlement. The balance sheet also carries a $231.4 million uncertain tax reserve plus $53.6 million of related interest and penalties, the treatment of which hinges on how the April 2026 rescheduling order is implemented.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AAWH was trading at $0.35 on OTC in the Life Sciences sector, with a market capitalization of approximately $71.2M. The 52-week trading range was $0.34 to $1.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AAWH - Latest Insights

AAWH
Nov 12, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3503
Real-time Price: $0.3503 info
Change: $0 (0%) info
Market Cap: $71.186M info
AAWH
Aug 12, 2026, 5:13 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.415
Real-time Price: $0.3503 info
Change: -$0.0647 (-16%) info
Market Cap: $71.186M info
AAWH
Aug 12, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.415
Real-time Price: $0.3503 info
Change: -$0.0647 (-16%) info
Market Cap: $71.186M info
AAWH
Jul 09, 2026, 5:30 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.410
Real-time Price: $0.3503 info
Change: -$0.0597 (-15%) info
Market Cap: $71.186M info
AAWH
Jun 25, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.4475
Real-time Price: $0.3503 info
Change: -$0.0972 (-22%) info
Market Cap: $71.186M info